Year |
Citation |
Score |
2004 |
Johns DG, Ao Z, Naselsky D, Herold CL, Maniscalco K, Sarov-Blat L, Steplewski K, Aiyar N, Douglas SA. Urotensin-II-mediated cardiomyocyte hypertrophy: effect of receptor antagonism and role of inflammatory mediators. Naunyn-Schmiedeberg's Archives of Pharmacology. 370: 238-50. PMID 15549273 DOI: 10.1007/s00210-004-0980-z |
0.329 |
|
2004 |
Douglas SA, Naselsky D, Ao Z, Disa J, Herold CL, Lynch F, Aiyar NV. Identification and pharmacological characterization of native, functional human urotensin-II receptors in rhabdomyosarcoma cell lines. British Journal of Pharmacology. 142: 921-32. PMID 15210573 DOI: 10.1038/sj.bjp.0705743 |
0.452 |
|
2004 |
Behm DJ, Herold CL, Camarda V, Aiyar NV, Douglas SA. Differential agonistic and antagonistic effects of the urotensin-II ligand SB-710411 at rodent and primate UT receptors. European Journal of Pharmacology. 492: 113-6. PMID 15178353 DOI: 10.1016/j.ejphar.2004.03.059 |
0.6 |
|
2004 |
Herold CL, Qi AD, Harden TK, Nicholas RA. Agonist versus antagonist action of ATP at the P2Y4 receptor is determined by the second extracellular loop. The Journal of Biological Chemistry. 279: 11456-64. PMID 14670966 DOI: 10.1074/Jbc.M301734200 |
0.594 |
|
2003 |
Herold CL, Behm DJ, Buckley PT, Foley JJ, Wixted WE, Sarau HM, Douglas SA. The neuromedin B receptor antagonist, BIM-23127, is a potent antagonist at human and rat urotensin-II receptors. British Journal of Pharmacology. 139: 203-7. PMID 12770925 DOI: 10.1038/sj.bjp.0705251 |
0.701 |
|
2002 |
Behm DJ, Herold CL, Ohlstein EH, Knight SD, Dhanak D, Douglas SA. Pharmacological characterization of SB-710411 (Cpa-c[D-Cys-Pal-D-Trp-Lys-Val-Cys]-Cpa-amide), a novel peptidic urotensin-II receptor antagonist. British Journal of Pharmacology. 137: 449-58. PMID 12359626 DOI: 10.1038/sj.bjp.0704887 |
0.437 |
|
2000 |
Kennedy C, Qi AD, Herold CL, Harden TK, Nicholas RA. ATP, an agonist at the rat P2Y(4) receptor, is an antagonist at the human P2Y(4) receptor. Molecular Pharmacology. 57: 926-31. PMID 10779375 |
0.624 |
|
1997 |
Herold CL, Li Q, Schachter JB, Harden TK, Nicholas RA. Lack of nucleotide-promoted second messenger signaling responses in 1321N1 cells expressing the proposed P2Y receptor, p2y7. Biochemical and Biophysical Research Communications. 235: 717-21. PMID 9207227 DOI: 10.1006/Bbrc.1997.6884 |
0.577 |
|
Low-probability matches (unlikely to be authored by this person) |
1994 |
Ichiki T, Herold CL, Kambayashi Y, Bardhan S, Inagami T. Cloning of the cDNA and the genomic DNA of the mouse angiotensin II type 2 receptor. Biochimica Et Biophysica Acta. 1189: 247-50. PMID 8292631 DOI: 10.1016/0005-2736(94)90072-8 |
0.273 |
|
2003 |
GANSLMAYER M, HEROLD C, OCKER M, HAHN E, SCHUPPAN D. 1254 Effectivity of a combination of the anti-estrogen tamoxifen and 9cis-retinoic acid in rat HCC model Hepatology. 38: 764-765. DOI: 10.1016/S0270-9139(03)81292-2 |
0.066 |
|
1997 |
Herzyk DJ, Ruggieri EV, Cunningham L, Polsky R, Herold C, Klinkner AM, Badger A, Kerns WD, Bugelski PJ. Single-organism model of host defense against infection: A novel immunotoxicologic approach to evaluate immunomodulatory drugs Toxicologic Pathology. 25: 351-362. PMID 9280118 |
0.061 |
|
Hide low-probability matches. |